Multiple nurses working on the same floor of busy hospital develop brain tumors
At least five nurses working on the same floor of a Boston-area hospital have been diagnosed with brain tumors, and they're looking for answers.
The nurse's union at the hospital, the Massachusetts Nurses Association (MNA), told Fox News Digital in a statement that it is actively supporting nurses at Newton-Wellesley Hospital in Newton, "who have brought forward serious medical concerns, focused on brain tumor diagnoses on the 5th floor maternity unit."
"We recognize that nurses and many other people want immediate information about the situation," the MNA continued. "This urgency comes from a place of concern for the health of nurses, their families, and patients — an urgency that we share."
The MNA further said it is working to "complete an independent, scientific investigation" into the diagnoses.
Nc State Alumni Report 150+ Cancer Cases Possibly Stemming From Contaminants In Shut-down Campus Building
"That effort is underway and may take additional weeks," the MNA said. "The investigation is being conducted by the MNA's division of health and safety, consisting of occupational health nurses, in collaboration with the Newton-Wellesley nurses."
Read On The Fox News App
In addition, the nurses' union said it has received more than 300 survey responses, emails and phone calls from current and former nurses, as well as other current and former hospital employees, regarding their health concerns.
105 People Diagnosed With Rare Cancers Are Allegedly Linked To A Nj High School, Survivor Seeks Answers
Newton-Wellesely reportedly conducted its own exam in December and found that through April, 11 staff members who worked, at some point and to varying degrees, on the fifth floor of the hospital, had been interviewed by the hospital's Occupational Health and Safety (OHS), according to a memo obtained by Boston.com.
The hospital determined that five cases were benign brain tumors of three different types, and six cases were determined not to be brain tumors at all but other health concerns, according to the memo.
New Jersey Township Investigating Mysterious 'Time Cohort' Cancer Cluster That May Be Linked To High School
The investigation further "found no environmental risks which could be linked to the development of a brain tumor," Jonathan Sonis, associate chief medical officer, and Sandy Muse, chief nursing officer, said in a statement to Boston.com.
"Based on these results, we can confidently reassure our dedicated team members at Mass General Brigham/Newton-Wellesley Hospital and all our patients that there is no environmental risk at our facility," the statement continued. "As always, the health and wellbeing of our staff, clinicians, and patients is our absolute top priority."
The OHS review did find that there were 668 X-rays performed with portable machines on the fifth floor of Newton-Wellesley between 2020 and 2024, doubling the risk of radiation exposure compared to normal daily radiation exposure for nurses standing approximately one meter from the machine, according to Boston.com.
"Even if a staff member had been present for all of these X-rays, however, they would not have absorbed this much exposure (i.e., one meter from the machine) as we utilize appropriate X-ray safety techniques throughout the hospital," the memo obtained by the outlet states.
Newton-Wellesley did not immediately respond to an inquiry from Fox News Digital.
The MNA said it is working with the hospital, which it says "only spoke to a small number of nurses and their environmental testing was not comprehensive."
"The hospital cannot make this issue go away by attempting to provide a predetermined conclusion," the MNA added. "While we currently cannot release specific numbers or other diagnosis information, we are committed to being transparent about our findings when we have finished verifying the information we collect.
"Completing this step-by-step process is critical to providing the support Newton-Wellesley nurses deserve."Original article source: Multiple nurses working on the same floor of busy hospital develop brain tumors

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
an hour ago
- New York Times
Gun Deaths of Children Rose in States That Loosened Gun Laws, Study Finds
Firearm deaths of children and teenagers rose significantly in states that enacted more permissive gun laws after the Supreme Court in 2010 limited local governments' ability to restrict gun ownership, a new study has found. In states that maintained stricter laws, firearm deaths were stable after the ruling, the researchers reported, and in some, they even declined. Guns are the leading cause of death in the United States for people under 18. Dr. Jeremy Faust, an emergency room doctor at Massachusetts General Brigham Hospital in Boston, who was the study's lead author, said he was dismayed to find that most of the children's deaths were homicides and suicides. 'It's surprising how few of these are accidents,' Dr. Faust said. 'I always thought that a lot of pediatric mortality from guns is that somebody got into the wrong place, and I still think safe storage is important, but it's mostly homicides and suicides.' The study, published Monday in JAMA Pediatrics, examined the 13-year period after the June 2010 Supreme Court ruling that the Second Amendment, which protects an individual's right to bear arms, applies to state and local gun-control laws. The decision effectively limited the ability of state and local governments to regulate firearms. The researchers classified states into three categories based on their gun laws: most permissive, permissive and strict. They used a Centers for Disease Control and Prevention database to analyze firearm mortality trends from 1999 to 2010 — before the Supreme Court ruling — and compared them with the 13-year period afterward. Want all of The Times? Subscribe.


Business Wire
4 hours ago
- Business Wire
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at
Yahoo
5 hours ago
- Yahoo
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December 2024, received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The product development plan is designed to seek concurrence of the FDA under MUMS designation. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the Company to an extended 7-year period of exclusive marketing following approval or conditional approval, provided that the Company meets all requirements for maintaining the designation. Doxorubicin-containing microneedle array (D-MNA) is a patent protected dissovable transdermal patch with cellulose based microneedle arrays that are tip-loaded with doxorubicin. After application, the microneedles function by penetrating the strateum corneum layer of the skin, create a temporary microchannel, penetrate the tumor, dissolve and release doxorubicin into the target tumor, and eradicate the cancer cells. "In Veterinary Medicine, where there are only a handful of approved oncology drugs, we believe developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million," stated Dr. Raza Bokhari, Executive Chairman & CEO. "The submission to the FDA of a novel product development program may provide us a first mover advantage and sets the stage to consider other companion animal species and types of cancer." Squamous Cell Carcinoma (SCC) in Horses SCC is a mucocutaneous skin tumor in horses, primarily affecting adult or aged horses with white or partially white coats. Breeds like Appaloosa, Belgian, American Paint, and Pinto are particularly susceptible. SCC often develops in areas with minimal pigmentation and sparse hair, notably around mucous membranes. More specifically, tumors are mainly seen around the eyes, lips, nose, anus, and external genitalia. The overall incidence of SCC is 2-3% and recent estimates of the US horse population range from 6.6 to 7.25 million horses. Current treatment includes surgery to remove the largest mass, cryotherapy of the smaller mass, and local injection of a chemotherapy drug. In some cases, a topical chemotherapeutic drug will be prescribed in the form of drops (tumors near the eye) or cream (tumors in other parts of body). Additionally, some horses are put on an oral drug called piroxicam that may slow the return of the cancerous cells. Product Development Plan The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 50 horses presenting with external SCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The horses will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The horses will be assessed for outcomes over six (6) months from index dose. The primary effectiveness variable will be a veterinarian's assessment for complete clinical response of the target tumor at day 90 according to RECIST. The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability human study (SKNJCT-001) completed in March 2021. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC. The Company also has SKNJCT-003 Phase 2 clinical study currently underway in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President(610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations(305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding its comprehensive product development plan to treat external SCC for horses, the commencement of its development plan, the market opportunity a non-invasive treatment for equine SCC and the Company's opportunity to develop, gain approval for and commercialize its product to meet such opportunity, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit